Egypt's CBE issues EGP5b FRN T-bonds    EHA launches national telemedicine platform with support from Egyptian doctors abroad    Madbouly reviews strategy to localize pharmaceutical industry, ensure drug supply    Egypt's real estate market faces resale slowdown amid payment pressures    Al-Mashat tells S&P that Egypt working to reduce external debt, empower private sector    Cairo's real estate market shows resilient growth as economy stabilizes: JLL    Egypt's Foreign Minister, Pakistani counterpart meet in Doha    Egypt condemns terrorist attack in northwest Pakistan    Emergency summit in Doha as Gaza toll rises, Israel targets Qatar    Egypt renews call for Middle East free of nuclear weapons، ahead of IAEA conference    Egypt's EDA, Korean pharma firms explore investment opportunities    Egypt's FM heads to Doha for talks on Israel escalation    Egypt advances plans to upgrade historic Cairo with Azbakeya, Ataba projects    Egyptian pound ends week lower against US dollar – CBE    Egypt hosts G20 meeting for 1st time outside member states    Lebanese Prime Minister visits Egypt's Grand Egyptian Museum    Egypt to tighten waste rules, cut rice straw fees to curb pollution    Egypt seeks Indian expertise to boost pharmaceutical industry    Egypt prepares unified stance ahead of COP30 in Brazil    Egypt recovers collection of ancient artefacts from Netherlands    Egypt harvests 315,000 cubic metres of rainwater in Sinai as part of flash flood protection measures    Egyptian, Ugandan Presidents open business forum to boost trade    Al-Sisi says any party thinking Egypt will neglect water rights is 'completely mistaken'    Egypt's Sisi warns against unilateral Nile measures, reaffirms Egypt's water security stance    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt, Huawei explore healthcare digital transformation cooperation    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



EIPICO targets 2023 start of Biosimilar Project with EGP 400-600m revenues in 1st year
Local market size for oncology and hormone-based products is estimated at EGP1.5bn, which is currently 100% imported
Alyaa Stohy Published in Daily News Egypt on 24 - 02 - 2021

The Egyptian International Pharmaceutical Industries Company (EIPICO) is looking to start operations at its Biosimilar Project in 2023, a source has exclusively told Daily News Egypt.
The source also said that the company is targeting EGP 400-600m in the first year of operations, which is expected to increase to EGP 2bn by 2030.
The local market size for the oncology and hormone-based products is estimated at around EGP1.5bn, that is currently 100% imported. With EIPICO being one of the first local producers in this area, the company expects to cover at least 50% of the local demand before exporting through its Biosimilar Project. The total cost of the project is around EGP1.2bn, to be financed using 1:1 debt to equity.
According to management, EIPICO secured the local currency denominated debt financing portion from local banks, with management also noting that the equity portion should be financed from the company's internal resources.
However, some of the company's shareholders favour the capital increase over internal financing, which means that a capital increase is on the table.
EIPICO plans to invest around EGP 169m in 2021, directed towards the purchase of new machinery for EIPICO 1 and EIPICO 2. These service the production and packaging of ointments and pills along with facility renovations.
The company plans to invest around EGP 800m over the next three years excluding the biosimilar project, directed towards operating, re-modelling and renewing the facilities machinery.
The company has invested around EGP 300-340m between 2019 and 2020, directed towards up-grading and renovating existing facilities, resulting in an increase of EGP 73m in revenues per annum.
EIPICO currently has a total portfolio of 611 products, of which 407 are registered, 129 are in the pipeline, 43 are veterinary, 30 are feed additives and two are biocides.
The company had 14 new launches in 2020, up from eight launches in 2019, translating into sales of EGP 39.1m (ex-factory) in 2020, and EGP 15.7m (ex-factory) in 2019.
The company's management has increased the prices of 29 products in 2020, compared to 12 products in 2019. This implies an increase of EGP 56.6m in sales (ex-factory) in 2020, compared to an increase of EGP 12.2m in sales (ex-factory) during 2019.
Management plans to focus on new launches at high ASP along with submitting re-pricing requests of the existing products to the regulatory authorities. This should bode well for the sales growth during 2021 and going forward.

Clic here to read the story from its source.